Breli Bonheur Ngouama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Breli Bonheur Ngouama has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ayola Akim Adegnika
Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
2 shared publications - Claujens Chastel Mfoutou Mapanguy
Fondation Congolaise pour la Recherche Médicale, Brazzaville P.O. Box 2672, Congo
2 shared publications - Darrel Ornelle Elion Assiana
Faculté des Sciences et Techniques, Université Marien NGOUABI, Brazzaville P.O. Box 69, Congo
2 shared publications - Francine Ntoumi
Fondation Congolaise pour la Recherche Médicale, Brazzaville P.O. Box 2672, Congo
2 shared publications - Franck Hardain Okemba Okombi
Programme National de Lutte contre la Tuberculose, Brazzaville P.O. Box 1066, Congo
2 shared publications - Freisnel Hermeland Mouzinga
Fondation Congolaise pour la Recherche Médicale, Brazzaville P.O. Box 2672, Congo
2 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 8999
Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo
Tuberculosis (TB) remains a major global public health concern, further complicated by the emergence and transmission of drug-resistant strains. Diversity within the Mycobacterium tuberculosis complex (MTBC) may also influence disease progression and treatment response. We conducted a longitudinal study among 126 Xpert MTB/RIF Ultra-confirmed TB patients enrolled and followed at the Antituberculosis Center of Brazzaville between July 2023 and November 2024. MTBC species were identified using the Genotype MTBC assay, and resistance-associated mutations in rpoB, katG, and embB were characterized by targeted Oxford Nanopore sequencing and interpreted using the WHO mutation catalogue and TB-Profiler. The overall treatment success rate was 81.7% (103/126). Among 109/126 samples successfully typed, M. tuberculosis accounted for 92.7% (101/109), Mycobacterium africanum for 3.7% (4/109), while mixed infection accounted for 0.9% (1/109) and inconclusive profiles for 2.8% (3/109). Resistance-associated mutations were assessed in 65 of the 126 enrolled patients with high-quality sequencing data. Among these 65 isolates, 32.3% (21/65) harbored resistance to at least one of the targeted first-line drugs, including isoniazid (23.1%; 15/65), rifampicin (15.4%; 10/65), and ethambutol (9.2%; 6/65). Multidrug-resistant TB was identified in 12.3% (8/65). The predominant mutations occurred at rpoB codon 435, katG codon 315, and embB codon 306. Treatment success was lower among patients infected with strains carrying a resistance-associated mutation (71.4%). Isoniazid resistance was associated with reduced odds of treatment success in unadjusted analysis (OR = 0.22, 95% CI: 0.05–0.93; p = 0.04). These findings suggest a considerable burden of genotypically predicted first-line drug resistance and support expanding molecular drug-susceptibility testing beyond rifampicin in TB surveillance and patient management in the Republic of Congo.
- 11 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 8999
Open AccessTargeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo
Tuberculosis (TB) remains a major global public health concern, further complicated by the emergence and transmission of drug-resistant strains. Diversity within the Mycobacterium tuberculosis complex (MTBC) may also influence disease progression and treatment response. We conducted a longitudinal study among 126 Xpert MTB/RIF Ultra-confirmed TB patients enrolled and followed at the Antituberculosis Center of Brazzaville between July 2023 and November 2024. MTBC species were identified using the Genotype MTBC assay, and resistance-associated mutations in rpoB, katG, and embB were characterized by targeted Oxford Nanopore sequencing and interpreted using the WHO mutation catalogue and TB-Profiler. The overall treatment success rate was 81.7% (103/126). Among 109/126 samples successfully typed, M. tuberculosis accounted for 92.7% (101/109), Mycobacterium africanum for 3.7% (4/109), while mixed infection accounted for 0.9% (1/109) and inconclusive profiles for 2.8% (3/109). Resistance-associated mutations were assessed in 65 of the 126 enrolled patients with high-quality sequencing data. Among these 65 isolates, 32.3% (21/65) harbored resistance to at least one of the targeted first-line drugs, including isoniazid (23.1%; 15/65), rifampicin (15.4%; 10/65), and ethambutol (9.2%; 6/65). Multidrug-resistant TB was identified in 12.3% (8/65). The predominant mutations occurred at rpoB codon 435, katG codon 315, and embB codon 306. Treatment success was lower among patients infected with strains carrying a resistance-associated mutation (71.4%). Isoniazid resistance was associated with reduced odds of treatment success in unadjusted analysis (OR = 0.22, 95% CI: 0.05–0.93; p = 0.04). These findings suggest a considerable burden of genotypically predicted first-line drug resistance and support expanding molecular drug-susceptibility testing beyond rifampicin in TB surveillance and patient management in the Republic of Congo.
- Open Access
- 10 February 2026
- Published by MDPI AG in Zoonotic Diseases
- Vol. 6 (1) , 5
Molecular Characterization of Drug Resistance-Associated Mutations in Mycobacterium tuberculosis Isolates from the Republic of Congo Using Targeted Nanopore Sequencing
Tuberculosis (TB) remains a major public health challenge, particularly in sub-Saharan Africa, where the emergence of drug-resistant MTB undermines current control efforts. This study aimed to characterize genetic mutations associated with resistance to first- and second-line injectable drugs in MTB isolates from pulmonary TB patients in the Republic of Congo. A total of 45 culture-positive MTB isolates collected between 2018 and 2019 were analyzed using targeted next-generation sequencing on the MinION device. Resistance-associated genes, including rpoB, katG, embB, gyrA, and rrs, were examined. Overall, 22/45 isolates (48%) harbored at least one mutation associated with drug resistance. Among resistant isolates, rifampicin resistance was detected in 15 of 22 (68.2%), predominantly associated with mutations in the rpoB rifampicin resistance–determining region, including p.Ser531Leu, p.Asp516Val, and p.His526Tyr.Ethambutol resistance was observed in 11 of 22 isolates (50.0%) and was mainly associated with the embB p.Met306Val mutation. Isoniazid resistance was detected in 9 of 22 isolates (40.9%), primarily associated with the KatG p.Ser315Thr mutation. Fluoroquinolone resistance was identified in 2 of 22 isolates (9.1%), mainly associated with gyrA p.Ala90Val and p.Asp94Gly mutations. Resistance to second-line injectable drugs was detected in 1 of 22 isolates (4.5%) and was associated with the rrs p.Ala1401Gly mutation. These findings underscore the need to enhance molecular surveillance and strengthen treatment protocols for drug-resistant TB in the Republic of Congo to effectively combat this evolving health crisis.
- 10 February 2026
- Published by MDPI AG in Zoonotic Diseases
- Vol. 6 (1) , 5
Open AccessMolecular Characterization of Drug Resistance-Associated Mutations in Mycobacterium tuberculosis Isolates from the Republic of Congo Using Targeted Nanopore Sequencing
Tuberculosis (TB) remains a major public health challenge, particularly in sub-Saharan Africa, where the emergence of drug-resistant MTB undermines current control efforts. This study aimed to characterize genetic mutations associated with resistance to first- and second-line injectable drugs in MTB isolates from pulmonary TB patients in the Republic of Congo. A total of 45 culture-positive MTB isolates collected between 2018 and 2019 were analyzed using targeted next-generation sequencing on the MinION device. Resistance-associated genes, including rpoB, katG, embB, gyrA, and rrs, were examined. Overall, 22/45 isolates (48%) harbored at least one mutation associated with drug resistance. Among resistant isolates, rifampicin resistance was detected in 15 of 22 (68.2%), predominantly associated with mutations in the rpoB rifampicin resistance–determining region, including p.Ser531Leu, p.Asp516Val, and p.His526Tyr.Ethambutol resistance was observed in 11 of 22 isolates (50.0%) and was mainly associated with the embB p.Met306Val mutation. Isoniazid resistance was detected in 9 of 22 isolates (40.9%), primarily associated with the KatG p.Ser315Thr mutation. Fluoroquinolone resistance was identified in 2 of 22 isolates (9.1%), mainly associated with gyrA p.Ala90Val and p.Asp94Gly mutations. Resistance to second-line injectable drugs was detected in 1 of 22 isolates (4.5%) and was associated with the rrs p.Ala1401Gly mutation. These findings underscore the need to enhance molecular surveillance and strengthen treatment protocols for drug-resistant TB in the Republic of Congo to effectively combat this evolving health crisis.